Skip to main
PTCT

PTC Therapeutics (PTCT) Stock Forecast & Price Target

PTC Therapeutics (PTCT) Analyst Ratings

Based on 12 analyst ratings
Buy
Strong Buy 33%
Buy 33%
Hold 25%
Sell 0%
Strong Sell 8%

Bulls say

PTC Therapeutics is poised for growth due to its diversified therapeutic portfolio, successful commercial products, and promising pipeline in rare disorders, indicating a long-term opportunity. The company's strong leadership with high female representation and focus on developing different modalities make it well-positioned for future success. While risks remain, including uncertainty in launch sustainability, a downside scenario may present a potential entry point as PTC continues to solidify its balance sheet and pursue profitable growth.

Bears say

PTC Therapeutics is facing sustainability issues related to manufacturing, data transparency, and clinical trial conduct, and drug pricing, which may affect its long-term growth prospects. Additionally, its significant exposure to international markets could bring unique challenges. While the potential for Sephience and early signals from PTC518 could bring short-term success, a slowdown in uptake and developmental/regulatory delays could result in a downside scenario for the company. Furthermore, PTC Therapeutics has not fully monetized its double-digit royalties on Evrysdi, leaving potential revenue on the table.

PTC Therapeutics (PTCT) has been analyzed by 12 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 33% recommend Buy, 25% suggest Holding, 0% advise Selling, and 8% predict a Strong Sell.

This aggregate rating is based on analysts' research of PTC Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About PTC Therapeutics (PTCT) Forecast

Analysts have given PTC Therapeutics (PTCT) a Buy based on their latest research and market trends.

According to 12 analysts, PTC Therapeutics (PTCT) has a Buy consensus rating as of May 22, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $88, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $88, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

PTC Therapeutics (PTCT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.